Increased Galectin-9 Expression, a Prognostic Biomarker of AGVHD, Regulates the Immune Response Through the Galectin-9 Induced MDSC Pathway After Allogeneic Hematopoietic Stem Cell Transplantation
Overview
Pharmacology
Authors
Affiliations
Galectin-9 (Gal-9) is a β-galactoside-binding soluble lectin family member that exerts its primary biological functions via specific glycoconjugate interactions. Gal-9 expression is closely related to tumor occurrence, development, metastasis and prognosis. In transplant immunology, a high level of Gal-9 expression has been shown to markedly reduce the severity of acute graft rejection and effectively prolong survival time in organ and bone marrow transplantation (BMT) models. The main mechanism of Gal-9-mediated immunoregulation involves the Tim-3/Gal-9 axis in T cells. However, myeloid-derived suppressor cell (MDSC) accumulation in transgenic mice with persistently high Gal-9 expression was observed in a model of lung inflammation, indicating that a potential immunosuppressive mechanism distinct from the Gal-9/Tim-3 axis might exist. In the present study, increased Gal-9 expression and MDSC frequencies before acute graft-versus-host disease (aGVHD) onset were observed in patients who developed aGVHD. Patients with higher Gal-9 expression (≥14.8417 ng/ml) exhibited reduced overall survival and increased cumulative incidences of GVHD at +100 day. We considered the elevated Gal-9 expression before aGVHD onset a secondary inflammatory response. This increase might be part of a negative feedback pathway corresponding to aGVHD pathogenesis. Additionally, a high Gal-9 concentration induced MDSC proliferation in vivo and in vitro. Gal-9-induced MDSCs (G9-MDSCs) suppressed T cell proliferation and activation. An infusion of G9-MDSCs into a graft contributed to the successful control of severe aGVHD and long-term survival in an allogeneic (allo)-BMT mouse model. Thus, we speculated that increased Gal-9 expression after allo-hematopoietic stem cell transplantation is a potential prognostic biomarker of aGVHD. The Gal-9-associated immunosuppressive effects on aGVHD development might occurr through G9-MDSCs and were independent of the Gal-9/Tim-3 axis.
Li M, Zhao X Chin Med J (Engl). 2024; 137(22):2697-2711.
PMID: 38973293 PMC: 11611246. DOI: 10.1097/CM9.0000000000003195.
Jansen S, Cutilli A, de Koning C, van Hoesel M, Frederiks C, Saiz Sierra L iScience. 2024; 27(6):110072.
PMID: 38883813 PMC: 11176658. DOI: 10.1016/j.isci.2024.110072.
Pang N, Tudahong S, Zhu Y, He J, Han C, Chen G Immun Inflamm Dis. 2024; 12(2):e1177.
PMID: 38353382 PMC: 10865418. DOI: 10.1002/iid3.1177.
Wang Y, Sun Y, Deng S, Liu J, Yu J, Chi H Cell Rep Med. 2024; 5(1):101374.
PMID: 38232701 PMC: 10829871. DOI: 10.1016/j.xcrm.2023.101374.
Pang N, Yu M, Xu J, Yuan H, Chen G, Wang D Braz J Med Biol Res. 2023; 56:e12997.
PMID: 38126537 PMC: 10729645. DOI: 10.1590/1414-431X2023e12997.